Through cellular biology and a clinically relevant model of asthma, they validated that the lead compound TSG12, which relaxed the bronchial smooth muscle, had promising clinical applications as a potential anti-asthmatic drug, and they demonstrated that activation of the transgelin-2 led to bronchial smooth muscle relaxation via the “calcium sensitization” pathway (Yuan et al., 2022). This evidence concerns the gene TAGLN2 and asthma.